Further analyses suggested that the high expression levels of PODNL1 were significantly associated with the poor OS of patients from the enumerated immunotherapeutic cohorts (the IMvigor210 cohort of mUC treated with anti-PD-L1 (Figure 8A–D), the GSE78220 cohort with the melanoma treated with anti-PD-1 (Figure 8E–H), as well as the cohorts of the patients treated with anti-CTLA4 (Figure 8I), and the cohorts of the patients treated with anti-PD-1 (Figure 8J) immunotherapies, analyzed by the K-M platform. This evidence concerns the gene PODNL1 and melanoma.